Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 2103-2115

  Lu, Xin Sui ^a   Sun, Wei ^b   Ge, Chun Yan ^a   Zhang, Wen Zhong ^a   Fan, Yue Zu ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

3 dimensional matrix; Gallbladder neoplasm; Signaling pathway; Vasculogenic mimicry; Xenograft model

Indexed keywords

EPHRIN RECEPTOR A2; GELATINASE A; MATRIX METALLOPROTEINASE 14; PAXILLIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOLECULAR MIMICRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; TUMOR SEEDING; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULOGENIC MIMICRY; WESTERN BLOTTING;

ANIMALS; FEMALE; FOCAL ADHESION KINASE 1; GALLBLADDER NEOPLASMS; HUMANS; LAMININ; MALE; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PAXILLIN; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPHA2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876514901     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1897     Document Type: Article

References (56)

1. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J Surg 196: 252-264, 2008. (Pubitemid 351970506)
2. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G and Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51: 349-364, 2001. (Pubitemid 34232782)
3. Reddy SK and Clary BM: Surgical management of gallbladder cancer. Surg Oncol Clin North Am 18: 307-324, 2009.
4. Li LD, Zhang SW, Lu FZ, Mu R, Sun XD and Huangpu XM: Research on characteristics of mortality spectrum and type composition of malignant tumors in China. Zhonghua Zhongliu Zazhi 19: 323-328, 1997.
5. Hsing AW, Gao YT, Devesa SS, Jin F and Fraumeni JF Jr: Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer 75: 368-370, 1998. (Pubitemid 28100037)
6. Chakravarty KD, Yeh CN, Jan YY and Chen MF: Factors infuencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 79: 151-157, 2009.
7. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, Zheng H, Lauwers GY and Ferrone CR: Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg 144: 441-447, 2009.
8. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M and Sato T: Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 66: 138-142, 2004. (Pubitemid 38608381)
9. Morise Z, Sugioka A, Tanahashi Y, Okabe Y, Ikeda M, Kagawa T and Takeura C: Treatment of patients with unresectable advanced carcinoma of biliary tract chemotherapy and surgical resection. Anticancer Res 29: 1783-1786, 2009.
10. Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK and Shukla PJ: Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther 2: 52-56, 2006. (Pubitemid 43926441)
11. Mojica P, Smith D and Ellenhorn J: Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 96: 8-13, 2007. (Pubitemid 47015442)
12. Shukla PJ and Barreto SG: Gallbladder cancer: we need to do better! Ann Surg Oncol 16: 2084-2085, 2009.
13. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Peer J, Trent JM, Meltzer PS and Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vascu-logenic mimicry. Am J Pathol 155: 739-752, 1999. (Pubitemid 29426820)
14. Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, Gupta TK and Folberg R: Prognostic signifcance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7: 473-477, 2001. (Pubitemid 32707967)
15. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K and Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 99: 821-828, 2002. (Pubitemid 34575699)
16. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffn JE, Seftor EA and Hendrix MJ: The clinical signifcance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 1: 661-664, 2002.
17. Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X, Zhang W and Hao X: Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16: 693-698, 2006.
18. Guzman G, Cotler SJ, Lin AY, Maniotis AJ and Folberg R: A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med 131: 1776-1781, 2007. (Pubitemid 350294576)
19. Li M, Gu Y, Zhang Z, Zhang S, Zhang D, Saleem AF, Zhao X and Sun B: Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16: 259-266, 2010.
20. Baeten CI, Hillen F, Pauwels P, de Bruine AP and Baeten CG: Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52: 2028-2035, 2009.
21. Hess AR, Seftor EA, Seftor R E and Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63: 4757-4762, 2003. (Pubitemid 37022600)
22. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and Hendrix MJ: Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metallopro-teinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61: 6322-6327, 2001. (Pubitemid 32783230)
23. Seftor RE, Seftor EA, Kirschmann DA and Hendrix MJ: Targeting the tumor microenvironment with chemically modifed tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1: 1173-1179, 2002.
24. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJ: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190: 899-909, 2004. (Pubitemid 38561505)
25. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS and Hendrix MJ: Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 3250-3255, 2001. (Pubitemid 32695007)
26. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ and Hess AR: EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8: 279-288, 2009.
27. Hess AR, Margaryan N V, Seftor EA and Hendrix MJ: Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vascu-logenesis: role of the Eph receptors. Dev Dyn 236: 3283-3296, 2007. (Pubitemid 350276386)
28. Hess AR and Hendrix MJ: Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 5: 478-480, 2006. (Pubitemid 43340521)
29. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ and Hendrix MJ: Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 65: 9851-9860, 2005. (Pubitemid 41541464)
30. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan N V, Seftor RE, Miyagi Y and Hendrix MJ: Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 63: 5381-5389, 2003. (Pubitemid 37139855)
31. Wang JY, Sun T, Zhao XL, Zhang SW, Zhang DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional signifcance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther 7: 758-766, 2008.
32. Ge CY and Fan YZ: Vasculogenic mimicry and its molecules signaling pathways. Chin Med Abstr (Surg) 15: 344-350, 2006.
33. Fan YZ and Sun W: Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2: 117-127, 2010.
34. Fan YZ, Sun W, Zhang WZ and Ge CY: Vasculogenic mimicry in human primary gallbladder carcinoma and clinical signifcance thereof. Zhonghua Yi Xue Za Zhi 87: 145-149, 2007.
35. Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ, Zhang JT, Lu XS and Ye C: Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep 27: 1990-2002, 2012.
36. Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res 30: 46, 2011.
37. Link W, Rosado A, Fominaya J, Thomas JE and Carnero A: Membrane localization of all class I PI3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fbroblasts via Akt. J Cell Biochem 95: 979-989, 2005. (Pubitemid 41420145)
38. McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6: 149-156, 2000. (Pubitemid 30171365)
39. Noel A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A and Foidart JM: Emerging roles for proteinases in cancer. Invasion Metastasis 17: 221-239, 1997. (Pubitemid 29033880)
40. Stetler-Stevenson WG: Matrix metalloproteinases in angio-genesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241, 1999. (Pubitemid 29218293)
41. Seiki M: Membrane-type matrix metalloproteinases. APMIS 107: 137-143, 1999. (Pubitemid 29133533)
42. Chang C and Werb Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11: S37-S43, 2001.
43. Lafleur, MA, Handsley MM, Knauper V, Murphy G and Edwards DR: Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 115: 3427-3438, 2002. (Pubitemid 34994032)
44. Koike T, Vernon RB, Hamner MA, Sadoun E and Reed MJ: MT1-MMP, but not secreted MMPs, infuences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J Cell Biochem 86: 748-758, 2002. (Pubitemid 34839976)
45. Haas TL, Davis SJ and Madri JA: Three-dimensional type I collagen lattices induce coordinate expression of matrix metallo-proteinases MT1-MMP and MMP-2 inmicrovascular endothelial cells. J Biol Chem 273: 3604-3610, 1998. (Pubitemid 28109785)
46. Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V and Seftor RE: Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann NY Acad Sci 995: 151-161, 2003. (Pubitemid 36706622)
47. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C and Chen J: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026, 2002. (Pubitemid 35252975)
48. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO and Chen J: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 2-11, 2002. (Pubitemid 36330206)
49. Miao H, Burnett E, Kinch M, Simon E and Wang B: Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2: 62-69, 2000.
50. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC and Seftor RE: Expression and functional signifcance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 8018-8023, 2001. (Pubitemid 32642679)
51. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5: 228-233, 2006. (Pubitemid 43327544)
52. Schaller MD: Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20: 6459-6472, 2001. (Pubitemid 32977851)
53. Stetler-Stevenson WG, Krutzsch HC and Liotta LA: TIMP-2, a new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378, 1989.
54. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S and He C: Human 72-kDa type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase inhibitor. Proc Nati Acad Sci USA 86: 8207-8211, 1989. (Pubitemid 19286028)
55. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83: 775-779, 1991.
56. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51 (Suppl): S5054-S5059, 1991.